Inmune Bio (INMB) Income towards Parent Company (2018 - 2026)

Inmune Bio has reported Income towards Parent Company for 9 years, with the latest figure at -$6.1 million in Q1 2026.

• Quarterly Income towards Parent Company rose 68.51% year-over-year to -$6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$45.4 million (up 78.11% YoY) and the FY2025 annual result came in at -$82.1 million, down 20.15% from the prior year.
• Income towards Parent Company retreated to -$6.1 million in Q1 2026 per INMB's latest filing, from -$6.0 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at -$6.0 million in Q4 2025 and troughed at -$532.4 million in Q3 2022.
• A 5-year average of -$51.6 million and a median of -$9.3 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2023 and 2024: Income towards Parent Company soared 97.48% in 2023, then sank 1072.11% in 2024.
• Over 5 years, Income towards Parent Company stood at -$6.5 million in 2022, then slumped by 42.53% to -$9.3 million in 2023, then declined by 13.31% to -$10.5 million in 2024, then jumped by 42.65% to -$6.0 million in 2025, then slipped by 0.86% to -$6.1 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered -$6.1 million, -$6.0 million, and -$8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.